Skip to main content

Table 1 Patients’ baseline characteristics*

From: Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

  Ghrelin, n = 10 Placebo, n = 10
Age (years) 70.8 (6.4) 73.1 (5.6)
Sex (males/females) 10/0 9/1
BMI (kg/m2) 18.4 (2.4) 18.1 (2.3)
Cigarettes (pack-years) 59.1 (29.2) 64.8 (25.1)
Pulmonary function   
FEV1 (L) 0.83 (0.21) 0.82 (0.23)
%FEV1 (% predicted) 32.0 (9.4) 33.3 (10.5)
FEV1/FVC (%) 41.7 (7.6) 42.4 (8.0)
VC (L) 2.54 (0.42) 2.62 (0.50)
%VC (%) 79.6 (11.0) 86.1 (15.3)
IC (L) 1.63 (0.22) 1.74 (0.38)
DLco (% predicted) 61.3 (23.8) 72.4 (27.4)
Exercise capacity in ICPET   
Peak work rate (Watt) 36.0 (13.5) 34.0 (9.7)
Peak V o 2 mL / kg / min 13.3 (3.7) 13.4 (3.2)
Medications   
LAMA 7 5
SAMA 2 2
LABA 6 5
ICS 4 1
Methylxanthines 5 6
Comorbidity   
Angina pectoris 2 0
PVC 0 1
  1. Data are presented as means (SD) unless otherwise stated. BMI Body mass index, DLco Carbon monoxide diffusing capacity, FEV 1 Forced Expiratory Volume in one second, FVC Forced Vital Capacity, IC Inspiratory Capacity, ICPET Incremental Cardiopulmonary Exercise Test, ICS Inhaled Corticosteroids, LABA Long-Acting β2-Agonist, LAMA Long-Acting Muscarinic Antagonist, PVC Premature Ventricular Contraction, SAMA Short-Acting Muscarinic Antagonist, VC Vital Capacity. * The groups shown represent all treated patients. Medications were not mutually exclusive, and data are presented separately.